Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 4CNS 3Genitourinary 2Thoracic 1NET 1Dermatologic 1

Conditions

Neuroendocrine Tumors 35Carcinoid Tumor 8Adenoma, Islet Cell 6Neoplasms 5Neoplasm Metastasis 3Carcinoma, Neuroendocrine 3Neuroectodermal Tumors, Primitive 2Liver Neoplasms 2Gastro-enteropancreatic neuroendocrine tumor 2Carcinoma, Renal Cell 2Carcinoma, Hepatocellular 2Carcinoma 2Tuberous Sclerosis 1Thymus Neoplasms 1Pheochromocytoma 1Paraganglioma 1Pancreatic Neuroendocrine Tumors 1Pancreatic Neoplasms 1Neoplastic Cells, Circulating 1Multiple Endocrine Neoplasia Type 1 1Metatropic dwarfism 1Metastatic Digestive System Neuroendocrine Tumor G1 1Lymphoma, Follicular 1Lung Neoplasms 1Kidney Neoplasms 1Glioblastoma 1Gastroenteropancreatic Neuroendocrine Tumors 1Disease Progression 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Large Cell 1

Interventions

lutetium Lu 177 dotatate 43-Iodobenzylguanidine 3gallium Ga 68 dotatate 2Temozolomide 2Capecitabine 2177Lu-octreotide, DOTA(0)-Tyr(3)- 2veliparib 1vandetanib 1olaparib 1fludarabine phosphate 1copper dotatate CU-64 1cabozantinib 1atezolizumab 1Specimen Handling 1Quality of Life 1Patient Reported Outcome Measures 1Molecular Diagnostic Techniques 1Magnetic Resonance Spectroscopy 1Lutetium-177 1Lutetium 1Iodine-131 1Interleukin-13 1Immunotherapy 1Fluorodeoxyglucose F18 1Everolimus 1Erlotinib Hydrochloride 1Drug Therapy 1Cyclophosphamide 1Cryosurgery 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Pheochromocytoma × Everolimus × NET × Clear all
NCT00843531 2020-09-29

RAD001 and Erlotinib in Patients With Neuroendocrine Tumors

University of California, San Francisco

Phase 2 Terminated
17 enrolled 10 charts
CNSEndocrineNET

Carcinoid Tumor, Paraganglioma, Pheochromocytoma, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡